Trial Profile
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Interferon gamma-1b (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Apr 2023 Status changed from active, no longer recruiting to completed.
- 05 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 03 Dec 2020 Status changed from recruiting to active, no longer recruiting.